

Biotin Human PD-L1 (CD274) Protein (C-Fc-Avi)

Catalog Number:	801003, 801004
Size:	25 ug, 100 ug
Target Name:	PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1,
Regulatory Status:	RUO

PRODUCT DETAILS


Application:	ELISA, BLI
Format:	Liquid, Biotinylated
Expression Host:	HEK293
Species:	Human
Sources:	Recombinant Human PD-L1 (Phe19-Thr239) with C-terminus Fc-Avi tag is expressed in HEK293 cells. This protein was site-specifically labeled with Biotin by BirA ligase.
Accession Number:	Q9NZQ7
Molecular Weight:	The protein has a predicted molecular weight of 54 kDa and migrates at approximately 70 kDa on SDS-PAGE under DTT-reducing conditions.
Affinity Tag:	C-Fc-Avi
Purity:	>95% based on SDS-PAGE under reducing condition
Formulation:	1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level:	Not tested
Protein Concentration:	25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling:	Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

BACKGROUND INFORMATION

Programmed death-ligand 1 (PD-L1, also known as CD274 or B7-H1) is a type I transmembrane glycoprotein and a key immune checkpoint molecule in the B7 family. It is broadly expressed on immune cells (such as T cells, B cells, macrophages, and dendritic cells) and in various tissues, as well as on many tumor types. PD-L1 interacts with its receptor PD-1, expressed on activated T and B cells, to deliver inhibitory signals that suppress T cell proliferation, cytokine production, and cytolytic function. This interaction plays a critical role in maintaining immune homeostasis, preventing autoimmunity, and enabling immune evasion by tumors. Therapeutic antibodies targeting PD-L1 or PD-1 have shown significant clinical benefit in cancer immunotherapy by restoring T cell activity.

PD-L1 is also implicated in tolerance during pregnancy, chronic infections, and transplantation. It contains two extracellular Ig-like domains, and its expression can be induced by inflammatory cytokines such as IFN- γ .

PRODUCT DATA



Human PD-L1 (C-Fc-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the PD-L1 protein exceeds 85%.

This product is supplied subject to the terms and conditions at www.innocryo.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.